DrugPatentWatch Database Preview

Genus Lifesciences Company Profile

« Back to Dashboard

What is the competitive landscape for GENUS LIFESCIENCES, and what generic alternatives to GENUS LIFESCIENCES drugs are available?

GENUS LIFESCIENCES has nine approved drugs.

There are eight US patents protecting GENUS LIFESCIENCES drugs.

There are forty-four patent family members on GENUS LIFESCIENCES drugs in twenty-three countries and twenty-two supplementary protection certificates in eleven countries.

Summary for Genus Lifesciences

International Patents:	44
US Patents:	8
Tradenames:	8
Ingredients:	8
NDAs:	9

Drugs and US Patents for Genus Lifesciences

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genus Lifesciences	LEVOLET	levothyroxine sodium	TABLET;ORAL	021137-002	Jun 6, 2003		DISCN	No	No
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-002	Sep 14, 2016		RX	Yes	Yes
Genus Lifesciences	GOPRELTO	cocaine hydrochloride	SOLUTION;NASAL	209963-001	Dec 14, 2017		RX	Yes	Yes	10,016,407
Genus Lifesciences	POTASSIUM CHLORIDE	potassium chloride	SOLUTION;ORAL	206814-002	Dec 22, 2014	AA	RX	Yes	Yes
Genus Lifesciences	YOSPRALA	aspirin; omeprazole	TABLET, DELAYED RELEASE;ORAL	205103-001	Sep 14, 2016		RX	Yes	No	9,987,231

Paragraph IV (Patent) Challenges for GENUS LIFESCIENCES drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	Delayed-release Tablets	81 mg/40 mg		2016-10-14

International Patents for Genus Lifesciences Drugs

Country	Patent Number	Estimated Expiration
European Patent Office	2260837
Norway	20035275
China	102209529
Eurasian Patent Organization	200301321
South Korea	20110079641

Supplementary Protection Certificates for Genus Lifesciences Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1441735	08C0026	France		PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
1411900	C01411900/01	Switzerland		PRODUCT NAME: ESOMEPRAZOL + NAPROXEN; REGISTRATION NO/DATE: SWISSMEDIC 61330 06.05.2011
1411900	122012000052	Germany		PRODUCT NAME: NAPROXEN MIT ESOMEPRAZOL; NAT. REGISTRATION NO/DATE: 85145.00.00 20120202; FIRST REGISTRATION: GROSSBRITANNIEN PL 17901/0263 - 0001 20101105
0253310	SPC/GB95/010	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
1441735	SPC/GB08/020	United Kingdom		SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB08/020 GRANTED TO ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. IN RESPECT OF THE PRODUCT RALTEGRAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6346 DATED 05 JANUARY 2011 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 01 JANUARY 2023.

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Genus Lifesciences